Clearmind Medicine announced that the first participant has been dosed with its MEAI-based oral drug candidate, CMND-100, in a phase 1/2a clinical trial for the treatment of alcohol use disorder (AUD).
This marks the first-in-human trial of Clearmind’s 5-Methoxy-2-aminoindane (MEAI)-based candidate, a novel psychoactive aminoindane derivative that exerts a euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages. The drug represents a potential breakthrough in treating AUD — a condition affecting over 28 million adults in the U.S. alone — targeting the reduction of alcohol consumption and cravings through a novel mechanism of action.
“Dosing the first participant with CMND-100 in our study marks a landmark achievement towards the development of a new solution and offering new hope for the massive, underserved community suffering from alcoholism,” said Adi Zuloff-Shani, Ph.D, Clearmind CEO.
The trial will assess CMND-100’s safety and efficacy in reducing alcohol consumption. The study will be conducted at two leading research institutions in the U.S., Yale School of Medicine’s Department of Psychiatry and Johns Hopkins University School of Medicine. The Israeli trial will be conducted at the Israel Medical Center for Addiction located in Ramat Gan, Israel.